TSE Growth ・ Ticker 206A ・ Listed
Updated
Offer price
450 yen
First traded price
489 yen
Selling 100 shares at the first traded price would have produced a gain of 3,900 yen, before fees and tax. 100 shares is the minimum trading unit in Japan.
You can only enter this lottery through a broker underwriting it. The lead underwriter is SMBC Nikko Securities, which receives the largest allocation.
Broker pages are in Japanese. A comparison in English is on the brokers page.
A drug discovery venture in Fujisawa, Kanagawa that uses its own PepMetics technology to create drug candidates that block protein-to-protein binding, and develops them with pharmaceutical companies.
It earns money by offering its technology and libraries of candidate compounds to pharmaceutical companies for joint research, and by licensing out drug candidates it discovers (handing over the rights to develop and sell them), receiving joint research fees, upfront payments and milestone payments as development progresses. Two candidates are in clinical trials, both in Phase 2: E7386, a cancer drug candidate being developed by Eisai, and PRI-724, a liver cirrhosis drug candidate licensed to Ohara Pharmaceutical.
Alongside joint research on its partners' targets, it is putting effort into in-house programmes, where it chooses drug targets itself, creates candidate compounds and licenses them out to pharmaceutical companies, with several programmes aimed at cancer, fibrosis, obesity and metabolic disease and other conditions. Because revenue depends on when contracts with pharmaceutical companies are signed, the company has not disclosed an earnings forecast for the year to September 2026.
Read about this company in Japanese →Figures are taken from the offering documents and public sources, and are checked against two independent sources before publication. Nothing here is investment advice. Shares can and do open below their offer price.
